Clinical trials
Leukemia, Lymphocytic, Chronic, B-Cell trials in the United States with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
33 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 3 |
| 2001 | 4 |
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 1 |
| 2005 | 3 |
| 2008 | 2 |
| 2013 | 2 |
| 2016 | 1 |
| 2021 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 33 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chronic Lymphocytic Leukemia Research Consortium | 2 |
| Gilead Sciences | 2 |
| Herbert Irving Comprehensive Cancer Center | 2 |
| Jonsson Comprehensive Cancer Center | 2 |
| M.D. Anderson Cancer Center | 2 |
| Medical College of Wisconsin | 2 |
| Novacea | 2 |
| University of California, Davis | 2 |
| Corixa Corporation | 1 |
| East Valley Hematology and Oncology Medical Group | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 33 |
| Lymphoma | 21 |
| Lymphoma, Follicular | 20 |
| Lymphoma, Non-Hodgkin | 20 |
| Lymphoma, B-Cell, Marginal Zone | 18 |
| Lymphoma, Large B-Cell, Diffuse | 18 |
| Lymphoma, Mantle-Cell | 18 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 18 |
| Burkitt Lymphoma | 16 |
| Lymphoma, Large-Cell, Immunoblastic | 16 |
Trials
Showing 1 to 25 of 33. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.